Davis Polk & Wardwell and Jia Yuan Law Offices have advised Chinese clinical trial and research firm Hangzhou Tigermed Consulting on its $1.38 billion Hong Kong IPO, with Freshfields Bruckhaus Deringer and Zhong Lun Law Firm representing the sponsors.

Tigermed, which is already listed in Shenzhen, is the largest clinical research trial provider in mainland China. According to Reuters, Tigermed will sell 107.06 million shares in this IPO, which could make the deal the largest healthcare transaction in Asia this year, topping WuXi Biologics’ $984 million share placement in May.

The Jia Yuan Law Offices team advising on the deal was led by partners Wang Yuan and Fu Yangyuan.

Meanwhile, partners Zhang Jinquan, Zhu Ying, Zhong Yang and Li Xiang led the Zhong Lun Law Firm team.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.